Genentech is set to reintroduce Susvimo, a treatment for wet age-related macular degeneration, after a voluntary recall nearly 2 years ago. The FDA approved a post-approval supplement for the ocular implant that delivers ranibizumab through a port delivery platform. The implant is inserted during an outpatient procedure, with refills every 6 months using a specially designed needle. Updates were made to meet performance standards after the recall in 2022. Genentech aims to make Susvimo available in the coming weeks, providing an alternative to regular eye injections for patients with wet AMD. The company emphasizes its commitment to innovative retinal treatments.
Source link
Genentech to reintroduce Susvimo for wet AMD
